11 / 24
Page 47
Notes:
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
Pharmacology Congress 2017
July 24-25, 2017
July 24-25, 2017 Melbourne, Australia
8
th
World Congress on
Pharmacology and Toxicology
Effects of anandamide and agmatine on cisplatin-induced neurotoxicity
in vitro
Kevser Erol, Cigdem Cengelli Unel
and
Sule Aydin
Eskisehir Osmangazi University, Turkey
Objective:
Cisplatin is a widely used antineoplastic drug in the treatment of malignancies. Cannabinoids have shown analgesic
features in neuropathic pain models. Agmatine has also been shown to relieve neuropathic pain in different animal models.
The aim of this study was to investigate the
in vitro
effects of anandamide, a cannabinoid receptor agonist and agmatine on
cisplatin-induced neurotoxicity on primary dorsal root ganglia.
Materials & Methods:
Primary cultures of DRG were also prepared from 1-day old rats. The toxic effects of cisplatin were
evaluated by incubating the cells with cisplatin (50-500 μm). Concentration of 200 µm of cisplatin which showed submaximal
neurotoxicity was used alone and with 10-500 µmconcentration of agmatine or with anandamide (10-1000 µm) for determining
its possible neuroprotective activity. MTT assay was used to detect the toxicity of DRG cells. Results were evaluated by using
ELISA test system at a wavelength of 450 nm.
Results:
Cisplatin had concentration-dependent neurotoxic effects on DRG
in vitro
and high concentration of anandamide
attenuated cisplatin neurotoxicity. But agmatine could not alter the neurotoxic effect of cisplatin.
Conclusions:
We suggest that exogenous cannabinoid may represent a promising new protective strategy against cisplatin
neurotoxicity.
Biography
Kevser Erol has completed her PhD from Dicle University and Postdoctoral studies from Anadolu University, School of Medicine. She is the Director of
Department of Pharmacology and has published more than 125 papers in reputed journals.
kerol@ogu.edu.trKevser Erol et al., Clin Exp Pharmacol 2017, 7:4 (Suppl)
DOI: 10.4172/2161-1459-C1-020